Correction to: Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan

Correction to: Digestive Diseases and Sciences (2019) 64:815–822 10.1007/s10620-018-5365-0

The original version of the article unfortunately contained percentage errors in second and third paragraphs of GerdQ Score section. Below is the corrected version.

We performed a stratified analysis of patients with NERD and erosive esophagitis. The proportions of patients with sufficient relief in NERD were 38.5, 84.6, and 84.6% of 13 patients in the esomeprazole group and 22.2, 66.7, and 77.8% of 9 patients in the vonoprazan group at 1, 2, and 4 weeks, respectively. The proportions of patients with complete resolution in NERD were 23.1, 53.8, and 69.2% in the esomeprazole group and 22.2, 22.2, and 33.3% in the vonoprazan group at 1, 2, and 4 weeks, respectively. There were no significant differences in the rates of sufficient relief and complete resolution in NERD at 1, 2, or 4 weeks between the esomeprazole group and the vonoprazan group.

The proportions of patients with sufficient relief in erosive esophagitis were 66.7, 91.7, and 91.7% of 12 patients in the esomeprazole group and 69.2,76.9, and 84.6% of 13 patients in the vonoprazan group at 1, 2, and 4 weeks, respectively. The proportions of patients with complete resolution in erosive esophagitis were 33.3, 41.7, and 58.3% in the esomeprazole group and 46.2, 46.2, and 61.5% in the vonoprazan group at 1, 2, and 4 weeks, respectively. There were no significant differences in the rates of sufficient relief and complete resolution at 1, 2, or 4 weeks between the esomeprazole group and the vonoprazan group in erosive esophagitis.